Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 10/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 3/20 | 0.42 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439570 | 0.88 | CCNT1 (0.54) | CCNT1GSK3BDYRK1ACDK9CCNK | |
| SCHEMBL1439508 | 0.87 | CCNT1 (0.55) | CCNT1GSK3BDYRK1ACDK9CCNK | |
| SCHEMBL1439734 | 0.86 | CCNT1 (0.69) | CCNT1GSK3BDYRK1ACDK9CCNK | |
| SCHEMBL10285635 | 0.82 | CCNT1 (0.48) | CCNT1GSK3BDYRK1ACDK9CCNK | |
| SCHEMBL9949793 | 0.82 | FLT3 (0.54) | CCNT1CDK9CCNKCNR2FLT3 | |
| SCHEMBL10285395 | 0.81 | CDK9 (0.60) | CCNT1DYRK1ACDK9 | |
| SCHEMBL10285388 | 0.81 | CCNT1 (0.46) | CCNT1GSK3BDYRK1ACDK9 | |
| SCHEMBL1439939 | 0.80 | CCNT1 (0.52) | CCNT1CDK9CCNKFLT3PRKCQ | |
| SCHEMBL10285737 | 0.79 | CCNT1 (0.48) | CCNT1DYRK1ACDK9 | |
| SCHEMBL10285396 | 0.79 | CCNT1 (0.48) | CCNT1DYRK1ACDK9CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CCNT1 39/4885GSK3B 1536/4885DYRK1A 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.